Obinutuzumab, pomalidomide and zanubrutinib in newly diagnosed follicular lymphoma

Obinutuzumab, pomalidomide and zanubrutinib in newly diagnosed follicular lymphoma: A prospective, single-arm, single-center, exploratory study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500106075

Enrollment

Unknown

Registered

2025-07-17

Start date

2025-07-21

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

follicular lymphoma

Interventions

Experimental group:Obinutuzumab, pomalidomide and zanubrutinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >= 60 years old, or 18-60 years old but refusing chemotherapy; 2.Diagnosed with CD20 positive follicular lymphoma (FL), grade 1-3b; II-IV stage; 3.The patient is untreated or has not received standardized treatment; 4.Indications for the treatment of follicular lymphoma; 5.ECOG = 3 months; 7.The patient is fully informed and signs the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Diagnosed or treated with malignant tumors other than follicular lymphoma within the past year; 2.There is clinical evidence indicating the transformation of large cell lymphoma; 3.Non lymphoma related liver and kidney dysfunction: alanine aminotransferase (ALT)>3 times the upper limit of normal, aspartate aminotransferase (AST)>3 times the upper limit of normal, total bilirubin (TBIL)>2 times the upper limit of normal, blood creatinine>1.5 times the upper limit of normal; 4.Other serious medical diseases will affect the study (such as uncontrolled diabetes, gastric ulcer, other serious heart and lung diseases, etc.); 5.Serious or uncontrolled infections; 6.Central nervous system dysfunction with clinical manifestations; 7.The patient has undergone significant surgery within the past 30 days (excluding lymph node biopsy); 8.Pregnant or lactating women, women of childbearing age who have not taken contraceptive measures; 9.Allergic to the medication used; 10.Researchers believe that patients who are not suitable for inclusion;

Design outcomes

Primary

Measure	Time frame
Complete remission rate after 6 cycles of therapy;	—

Secondary

Measure	Time frame
Overall remission rate after 12 cycles of therapy;Overall remission rate after 6 cycles of therapy;Duration of tumor remission;Complete remission rate after 12 cycles of therapy;	—

Countries

China

Contacts

Public ContactWenjuan Yu

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

drwjyu@163.com+86 571 87235983

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026